Brenton Fargnoli
Partner @ Lightspeed Venture Partners
New York, United States
Brenton Fargnoli is a Series A investor at Lightspeed Venture Partners in New York focused on Health Care and Medical. Brenton Fargnoli is medical director of value-based care, and director of product marketing and strategy at Flatiron Health. Brenton led the team that launched Flatiron’s value-based care initiative and scaled it across the country. He now focuses on the launch and growth of Flatiron’s provider-facing products and services. Brenton is boardcertified in Internal Medicine, and a practicing oncology hospitalist.Brenton speaks frequently on the topic of value-based care, and his research has been published internationally including in Cancer Research and the ASCO Annual Meeting. He previously worked in J.P Morgan’s Healthcare Investment Banking Group, and at Blue Cross Blue Shield.Brenton completed his residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning his MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Brenton Fargnoli invests in
Stages Brenton Fargnoli invests in
Countries Brenton Fargnoli invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 12 (50%)
- Medical 5 (21%)
- Artificial Intelligence 5 (21%)
- Biotechnology 4 (17%)
- Software 3 (13%)
Stage
- Series A 7 (29%)
- Seed 6 (25%)
- Series B 3 (13%)
- Series C 3 (13%)
- Series D 2 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Assort Health
|
Assort Health is building healthcare that remembers.From call center automation and form intake to referrals, document processing, outreach, and payments, we manage the entire patient journey for providers. Our platform is the most widely used AI agents platform for the patient journey, built on 180 million specialty patient interactions and amodel that handles the complexity general-purpose AI can’t.Healthcare organizations see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score.With over $222M raised from Menlo Ventures, Lightspeed, First Round Capital, Apolo Ohno, and Joe Montana, Assort is becoming the standard for how providers use AI to transform the patient journey.Learn more at assorthealth.com | $120M / Series C / Jun 24, 2026 | |
Doctronic
|
Doctronic is the first D2C AI doctor working with human doctors in all 50 states in the US (and moving into other countries quickly). Get immediate AI diagnosis and then ask a human doctor to verify / act on that diagnosis if needed. | $40M / Series B / Mar 23, 2026 | |
Gyde
|
Gyde is an insurance technology company that operates an AI-native brokerage platform designed to support insurance professionals and agencies with digital tools and services. It provides an intelligent assistant that automates client outreach, scheduling, reminders, and routine communications to help brokers manage insurance, health, and wealthneeds. The company also offers a broker operating system that organizes meetings, captures context, and suggests cross-sell opportunities to streamline workflow. Gyde partners with agency owners through a model that integrates technology and operational support to augment traditional brokerage functions. Its platform is built to assist licensed agents in client service and administrative tasks while facilitating comprehensive advisory interactions. | Seed / Jan 28, 2026 | |
|
Gyde
|
Gyde is an insurance technology company that operates an AI-native brokerage platform designed to support insurance professionals and agencies with digital tools and services. It provides an intelligent assistant that automates client outreach, scheduling, reminders, and routine communications to help brokers manage insurance, health, and wealthneeds. The company also offers a broker operating system that organizes meetings, captures context, and suggests cross-sell opportunities to streamline workflow. Gyde partners with agency owners through a model that integrates technology and operational support to augment traditional brokerage functions. Its platform is built to assist licensed agents in client service and administrative tasks while facilitating comprehensive advisory interactions. | $60M / Series A / Jan 28, 2026 | |
|
Assort Health
|
Assort Health is building healthcare that remembers.From call center automation and form intake to referrals, document processing, outreach, and payments, we manage the entire patient journey for providers. Our platform is the most widely used AI agents platform for the patient journey, built on 180 million specialty patient interactions and amodel that handles the complexity general-purpose AI can’t.Healthcare organizations see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score.With over $222M raised from Menlo Ventures, Lightspeed, First Round Capital, Apolo Ohno, and Joe Montana, Assort is becoming the standard for how providers use AI to transform the patient journey.Learn more at assorthealth.com | $76M / Series B / Oct 02, 2025 | |
Thyme Care
|
Thyme Care is a healthcare company that provides oncology care management services. The company offers a patient- and provider-integrated oncology solution, partnering with health plans to facilitate whole-person care for their members. Thyme Care seeks to revolutionize cancer care by providing personalized and holistic support to patients. Thecompany envisions a future where every cancer patient can access high-quality, individualized care that meets their unique needs and circumstances. | $97M / Series D / Sep 25, 2025 | |
|
Doctronic
|
Doctronic is the first D2C AI doctor working with human doctors in all 50 states in the US (and moving into other countries quickly). Get immediate AI diagnosis and then ask a human doctor to verify / act on that diagnosis if needed. | $20M / Series A / Sep 15, 2025 | |
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M / Series D / Sep 10, 2025 | |
Neuralink
|
Neuralink develops implantable brain-computer interface (BCI) systems designed to facilitate direct communication between the human brain and external devices. The company focuses on creating a scalable neural implant that records and transmits brain signals with high precision. Neuralink's primary device, often referred to as a"Link," includes ultra-thin threads that are surgically placed in the brain to monitor neural activity and potentially stimulate it. These devices are intended for applications in medical treatment, such as helping individuals with paralysis regain motor function or communication capabilities. Neuralink also invests in developing robotic surgical systems to perform the implantation procedure with high accuracy and minimal invasiveness. The long-term goal involves enabling broader human-computer symbiosis, including interaction with artificial intelligence systems. | $649M / Series E / May 27, 2025 | |
Antares Therapeutics
|
Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M / Series A / May 15, 2025 | |
| See all 24 investments → | |||
Co-Investors
Lightspeed Venture Partners is a venture capital firm that engages in consumer, enterprise, technology, and cleantech markets. It focuses on seed, early-stage, later-stage, expansion-stage, start-ups, growth companies, and incubation, and specializes in debt financing for start-ups and growth companies.Lightspeed Venture Partners invests invarious sectors that include enterprise, consumer, big data, bitcoin, enterprise technology, cleantech, mobile, internet, financial technology, cloud solutions, e-commerce, storage, media, networking, energy, and software, software-as-a-service, information technology, biotechnology, and social.
Lightspeed Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Arsham Memarzadeh
Partner
|
|||
Galym Imanbayev
Partner
|
|||
James Ephrati
Partner
|
|||
Justin Overdorff
Partner
|
|||
Michael Mignano
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brenton Fargnoli invest in?
Brenton Fargnoli invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brenton Fargnoli?
Public channels for Brenton Fargnoli include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brenton Fargnoli last invest?
The most recent investment recorded for Brenton Fargnoli closed in Jun 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
